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 What ’ s known on the subject? and What does the study add? 
 Interstitial cystitis/painful bladder syndrome (IC/PBS) comprises pain perceived to be 
from the bladder, urinary urgency and frequency, and nocturia. As diagnosed at 
present, it is primarily identifi ed in adult women. It is a chronic disease yet its natural 
history has not been well studied. 
 In a prospective study of 304 incident female IC/PBS cases followed for a median of 
33 months after onset, women with baseline chronic fatigue syndrome had a worse 
prognosis for IC/PBS. Mild IC/PBS at baseline was the only variable that was directly 
associated with a good prognosis. 
 OBJECTIVE 
 •  To identify baseline variables that predict 
the prognosis of interstitial cystitis/painful 
bladder syndrome (IC/PBS) in women 
seeking medical care for recent onset of 
this syndrome. 
 SUBJECTS AND METHODS 
 •  In a prospective study of women with 
incident IC/PBS ( ≤ 12 months of symptoms), 
we contacted patients at intervals and 
asked standardized questions about IC/PBS 
symptoms in the previous week. 
 •  Logistic regression analyses assessed 
baseline variables as predictors of mild vs 
more severe IC/PBS at the last follow-up. 
 RESULTS 
 •  Median length of follow-up was 33 
months after onset of IC/PBS; 304 (97%) 
patients had at least one follow-up 
assessment. 
 •  Mild IC/PBS at baseline was the only 
variable that was directly associated with a 
mild IC/PBS endpoint. 
 •  Conversely, a history of chronic fatigue 
syndrome (CFS) was inversely associated 
with a mild endpoint of IC/PBS (i.e. 
individuals with CFS had a worse prognosis 
for their IC/PBS symptoms). 
 CONCLUSIONS 
 •  At a median of nearly 3 years 
after onset, baseline mild IC/PBS was 
directly associated with a milder disease 
severity. 
 •  Baseline co-morbid CFS was associated 
with more severe disease. 
 •  Whether CFS was uniquely associated 
or represented several co-morbid non-
bladder syndromes (NBSs) could not be 
determined. 
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 INTRODUCTION 
 Interstitial cystitis/painful bladder syndrome 
(IC/PBS) comprises pain perceived to be 
from the bladder, urinary urgency and 
frequency and nocturia. As diagnosed at 
present, it is primarily identifi ed in adult 
women. Its aetiology is unknown  [ 1 ] . 
 Interstitial cystitis/painful bladder syndrome 
is a chronic disease  [ 1 ] . In a prospective 
study of 304 incident female IC/PBS patients 
followed for a median of 33 months after 
onset, we reported that complete 
disappearance of IC/PBS symptoms was rare, 
but that improvement occurred in a 
substantial minority of patients  [ 2 ] . To 
provide data for discussions about prognosis 
with patients with recent-onset IC/PBS, we 
report here baseline factors that predicted 
differential clinical status at a median of 
nearly 3 years after onset of symptoms. 
 SUBJECTS AND METHODS 
 Events Preceding Interstitial Cystitis (EPIC) 
was a case – control study seeking risk 
factors for IC/PBS in women; methodological 
details are presented elsewhere  [ 2 – 5 ] . Briefl y, 
312 women aged  ≥ 18 years with a 
syndrome beginning within the previous 12 
months and lasting  ≥ 4 weeks that 
comprised pain that they perceived to be 
from the bladder ( ≥ 3 on a scale of 10) plus 
at least two of the symptoms of urgency 
( ≥ 3/10), frequency ( ≥ eight times/24  h) or 
nocturia ( ≥ once per night). Cases were 
recruited nationally through patient support 
groups and urologist and gynaecologist 
associations by letters, posters and the 
internet. 
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 This syndrome had to have been evaluated 
by at least one physician and patients were 
required to give permission to review 
medical records from 1 year before the 
onset of symptoms to the present. Of 1088 
medical records sought, 1062 (98%; 3.4/
patient) were obtained and reviewed to 
exclude mimicking diseases, confi rm the 
onset date of IC/PBS symptoms and record 
IC/PBS diagnostic and therapeutic initiatives 
 [ 6 ] . Respondents were excluded by self-
report or medical record evidence of 12 
possibly mimicking diseases as listed in the 
1990 defi nition of interstitial cystitis of the 
National Institute of Diabetes, Digestive and 
Kidney Diseases  [ 7 ] . Because of the 
possibility of a neurogenic bladder, 
exclusions also included stroke, spinal cord 
injury, Parkinson ’ s disease, multiple sclerosis 
and spina bifi da. The index date for cases 
was the onset date of the fi rst IC/PBS 
symptom and was identifi ed by a fi ve-step 
process: (i) estimate by the participant; (ii) 
probing questions about earlier symptoms; 
(iii) probing questions about similar episodes 
lasting  ≥ 4 weeks in the previous 5 years; 
(iv) medical record review; and (v) fi nal 
concurrence with the case. For enrolment, 
cases required medical record diagnosis of 
interstitial cystitis by a urologist or 
gynaecologist and/or treatment with 
IC/PBS-specifi c medications. 
 The characteristics of these patients  [ 6 ] were 
similar to those of previously reported 
patient series  [ 8,9 ] . The mean score of worst 
IC/PBS pain was 8.4/10. In all, 86% of cases 
reported this pain to worsen with bladder 
fi lling, 81% reported it to improve with 
voiding, and 83% reported it to worsen with 
certain dietary products; 97% reported one 
or more of these. The mean urgency was 
7.5/10, 87% had frequency of  ≥ 11/24  h and 
71% reported nocturia of  ≥ three times per 
night. The mean Interstitial Cystitis 
Symptom Score  [ 9 ] was 14.8. These cases 
met the defi nitions of IC/PBS of the Fourth 
International Consultation on Incontinence 
 [ 10 ] , the European Society for the Study of 
Interstitial Cystitis  [ 11 ] , and the AUA  [ 12 ] . 
 Controls were recruited by national random 
digit dialling, matched to cases by gender, 
age, region of the country and index date, 
and compared with cases on antecedent 
characteristics. 
 The baseline interview took place a mean of 
9 months after IC/PBS onset. Follow-up 
interviews took place at 6, 12, 18, 24, 36 
and 48 months after the baseline interview 
 [ 2 ] . Trained female interviewers performed 
all interviews by telephone; to the extent 
possible, the same interviewer contacted 
each patient over the course of the study. 
At the baseline interview and at each 
follow-up, the interviewer asked 
standardized questions about IC/PBS 
symptoms in the previous week. Pain and 
urgency were scored as 0 – 10 (10 being the 
worst imaginable), frequency as number of 
times/24  h. Composite IC/PBS symptom 
scores  [ 13 ] of none, mild, moderate or 
severe were constructed from scores of the 
individual symptoms of pain, urgency and 
frequency  [ 2 ] . At the baseline interview, fi ve 
(2%) patients had a composite score of 
none, 82 (26%) had a composite score of 
mild, 155 (50%) had a composite score of 
moderate and 70 (22%) had a composite 
score of severe IC/PBS. 
 At follow-up we defi ned remission as the 
absence of IC/PBS symptoms but found that 
few patients achieved remission and, for 
most of those who did, it was temporary  [ 2 ] . 
Because of the low incidence and instability 
of remissions, for the present study we 
defi ned the endpoint as a composite 
symptom score of mild or no IC/PBS 
symptoms at the last follow-up ( ‘ mild 
endpoint ’ )  [ 13 ] ; those who did not achieve 
this endpoint had either moderate or severe 
IC/PBS at the last follow-up ( ‘ moderate/
severe endpoint ’ ). 
 Three sets of baseline variables were 
assessed as potential prognostic factors. Two 
sets were of variables before the index 
date. The fi rst comprised the following 
demographics: age, race, religion, education 
and presence or absence of health 
insurance. The second set was of queried 
variables before the index date that 
distinguished cases from controls on 
bivariable analyses. These included pre-index 
date histories of: ever pregnant; use of birth 
control pills, female hormone therapy, 
douches and condoms; surgeries and 
abortions; sexual activity, dyspareunia and 
genital warts  [ 5,14,15 ] ; and 11 non-bladder 
syndromes (NBSs)  [ 4,15 ] . These NBSs 
included eight diagnosed by symptom-based 
expert consensus: chronic fatigue syndrome 
(CFS), fi bromyalgia (FM), irritable bowel 
syndrome (IBS), sicca syndrome, migraine, 
chronic pelvic pain (CPP), panic disorder and 
vulvodynia. The other three NBSs were 
allergy, diagnosed by self-report, and 
asthma and depression, scored if both 
physician diagnosis and medical therapy 
were reported. 
 The third set of variables described baseline 
IC/PBS: from medical records, the presence 
of Hunner ’ s ulcer or glomerulations; and 
from self-reports, sites of IC/PBS pain  [ 3 ] , 
severity of IC/PBS symptoms (see earlier), 
and IC/PBS therapy that had been prescribed 
between the index date and the baseline 
interview (baseline therapy). Therapies 
queried were bladder distension; bladder 
instillations with dimethylsulphoxide, 
heparin, hyaluronic acid, lidocaine or other; 
and systemic therapies including 
pentosanpolysulphate, amitriptylene, 
hydroxyzine, non-narcotic pain medications, 
narcotics, antispasmodics or other. 
 To assess confounding by IC/PBS treatment, 
the use of these therapies was also assessed 
between the previous and last follow-up 
(interval therapy). 
 Chi-squared and  t -tests screened each 
baseline variable for association with a mild 
endpoint. Associations with  P values  ≤ 0.10 
were entered into logistic regression 
analyses adjusted for demographics, 
duration of follow-up, and interval IC/PBS 
therapies. The present study was approved 
by the University of Maryland Institutional 
Review Board. 
 RESULTS 
 In all, 304 patients (97%) participated in 
at least one follow-up interview. The 
median duration of follow-up was 33 
months after the index date. At their last 
follow-up, 20 (7%) patients had no IC/PBS 
symptoms and 109 (36%) had mild 
symptoms, i.e. 129/304 (42%) had a mild 
endpoint. Of the remainder, 123 (40%) had 
moderate and 52 (17%) severe IC/PBS 
symptoms, i.e. 175 (58%) had a moderate/
severe endpoint. 
 In bivariable analyses, only mild IC/PBS at 
baseline was directly associated with a mild 
IC/PBS endpoint, but several baseline 
variables were inversely associated. All 
variables associated directly or inversely 
with a mild endpoint with  P  ≤ 0.10 are 
shown in  Table  1 . Each of these variables 
was entered into logistic regression analyses 
W A R R E N  E T  A L .
E 9 4  ©  2 0 1 2  B J U  I N T E R N A T I O N A L
before your index date, did you experience, 
for 6 months or longer, persistent fatigue 
that was not relieved with rest and that 
limited your activities? ’ Of the 85 patients 
who answered  ‘ yes ’ , 61 reported the other 
criteria for CFS ( ≥ 4 of impaired memory or 
concentration, sore throat, tender cervical or 
axillary lymph nodes, muscle pain, multi-
joint pain, new headaches, unrefreshing 
sleep, or post-exertion malaise) and 24 did 
not. Signifi cantly fewer of the 61 patients 
who met the criteria for CFS had a mild 
 TABLE  1  Baseline variables associated with a mild IC/PBS endpoint ( P  ≤ 0.10) 
Baseline variable




absent  P value
Mild IC/PBS 56/85 (66%) 73/219 (33%) *  < 0.001
Non-bladder syndromes
  CFS 12/61 (20%) 117/243 (48%)  < 0.001
  CPP 38/110 (35%) 91/194 (47%) 0.036
  Migraine 35/102 (34%) 94/202 (47%) 0.042
  Panic disorder 29/86 (34%) 100/218 (46%) 0.054
  FM 22/68 (32%) 107/236 (45%) 0.056
Number 0.001
  0 – 1 37/69 (54%)  – 
  2 – 5 86/199 (43%)  – 
  6 – 9 6/36 (17%)  – 
Reproductive
  Ever pregnant 86/222 (39%) 43/82 (52%) 0.032
  Lifetime  ≥ one/week douche 8/30 (27%) 121/274 (44%) 0.066
  Lifetime, always  + usually use condoms 20/61 (33%) 109/134 (45%) 0.088
IC/PBS therapy
  Bladder distension 71/187 (38%) 58/117 (50%) 0.046
  Narcotics 57/153 (37%) 72/151 (48%) 0.066
 * Absence of mild IC/PBS  = IC/PBS symptom score of moderate/severe. 
 TABLE  2  Logistic regression analyses for a mild IC/PBS endpoint (OR  [ 95% CI ] ) 
Variable
Analysis * 
1 2 3 4 5
Baseline variables
  Mild IC/PBS 3.7 (2.0 – 6.7) 3.6 (2.0 – 6.4) 3.6 (2.0 – 6.6) 3.5 (1.9 – 6.3) 3.6 (1.9 – 6.5)
  CFS 0.32 (0.14 – 0.75) ND 0.26 (0.11 – 0.61) ND 0.29 (0.11 – 0.71)
  6 – 9 non – bladder syndromes ND 0.29 (0.10 – 0.86) ND 0.27 (0.09 – 0.81) 0.64 (0.14 – 3.0)
  History of condom use 0.46 (0.23 – 0.94) 0.51 (0.26 – 1.0) 0.43 (0.21 – 0.88) 0.50 (0.25 – 1.0) 0.42 (0.21 – 0.87)
Interval IC/PBS therapy
  Narcotics ND ND 0.32 (0.15 – 0.71) 0.39 (0.18 – 0.85) 0.33 (0.15 – 0.73)
 * See text for details. ND, not done. Adjusted for age, race, religion, education, medical insurance and duration of follow-up. Variables listed are those 
signifi cant in at least one of these analyses. 
adjusted for age, race, religion, education, 
medical insurance and duration of follow-up 
( Table  2 ). Logistic analysis 1 included the 
fi ve NBSs that were inversely associated 
with a mild endpoint by bivariable analyses: 
CFS, CPP, migraine, panic disorder and FM. 
This logistic regression analysis revealed that 
three baseline variables remained associated: 
mild IC/PBS at baseline was directly 
associated, and CFS and history of condom 
use were inversely associated with a mild 
endpoint of IC/PBS. 
 We repeated the logistic regression analysis 
but for the individual NBSs, we substituted 
the number of NBSs (0 – 1, 2 – 5, and  ≥ 6 
NBSs) ( Table  2 , analysis 2). Baseline mild 
IC/PBS was still directly associated with a 
mild endpoint,  ≥ 6 NBSs was inversely 
associated, and condom use became 
non-signifi cant. 
 In logistic regression analyses 3 – 4 in 
 Table  2 , we sought to adjust for possible 
confounding. Because condoms are used 
to prevent pregnancies and sexually 
transmitted infections (STIs), number of 
pregnancies was substituted for  ‘ ever 
pregnant ’ and a new variable was added: 
lifetime history of STI, defi ned as self-report 
of  ≥ 1 of gonorrhoea, syphilis, HIV, genital 
chlamydia, warts or herpes. Interval 
therapies were integrated to adjust for 
possible confounding. The odds ratios (ORs) 
found in analyses 1 and 2 did not change 
substantively. Interval narcotic use was 
inversely associated with a mild endpoint. 
 In analysis 5 in  Table  2 , all variables in 
analyses 1 – 4 were included, specifi cally 
NBSs both as individual syndromes and as 
number of NBSs per patient. Only one 
variable substantively changed:  ≥ 6 NBSs 
was no longer signifi cantly associated. A 
history of CFS remained inversely associated 
with a mild endpoint. 
 Because of the inverse association with CFS, 
we hypothesized that fatigue alone at 
baseline might be predictive of a poor 
outcome of IC/PBS. The stem question that 
led to the series of queries about CFS 
symptoms was:  ‘ At any time in your life 
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endpoint (12, 20%) than did the 24 patients 
with  ≥ 6 months of fatigue but not the other 
criteria for CFS (12/24, 50%). Indeed 
the latter group was not signifi cantly 
different from patients who answered 
 ‘ no ’ , i.e. who did not have chronic fatigue 
before onset of IC/PBS (105/219, 48%). 
When fatigue as a symptom (i.e. in the 
85 patients) was substituted for CFS in 
analysis 5 in  Table  2 , it was not associated 
with a mild IC/PBS endpoint (OR  = 0.68, 
0.33 – 1.4). 
 A history of condom use was initially 
analysed as (always  + usually) vs (sometimes 
 + rarely  + never). In  Table  3 , we expanded 
this variable into these fi ve frequency-of-
use categories and observed no monotonic 
association with IC/PBS outcome. 
 DISCUSSION 
 In this prospective longitudinal study of 304 
incident IC/PBS patients, logistic regression 
analyses revealed two variables that 
predicted a mild IC/PBS endpoint: mild 
IC/PBS at baseline and absence of a history 
of CFS. 
 The association with mild IC/PBS at baseline 
with a mild endpoint was anticipated. Earlier 
we reported that most women with mild 
IC/PBS at baseline had mild IC/PBS at each 
follow-up  [ 2 ] . This is consistent with the 
observations of others that symptoms of 
IC/PBS generally reach a plateau rapidly 
after onset and then wax and wane about 
this level for years  [ 8,16,17 ] . 
 The association of CFS with a poor outcome 
of IC/PBS is perhaps the more interesting 
fi nding. It might be worth emphasizing that 
the observation is that CFS preceded the 
onset of IC/PBS; in other words, this 
association cannot be explained by 
symptoms of IC/PBS causing poor sleep 
and subsequent chronic fatigue. It should 
also be noted that full recovery from CFS 
is uncommon  [ 18 ] . CFS present before 
IC/PBS probably persisted after the onset of 
IC/PBS in most patients, but we did not 
query the continued presence of its 
symptoms. 
 The association of prior CFS with a poor 
outcome of subsequent IC/PBS suggests 
either that CFS was uniquely associated with 
a more severe outcome of IC/PBS or that it 
was a representative of several, co-morbid, 
NBSs. 
 If CFS itself is the important link to a poor 
outcome of IC/PBS, two hypotheses are 
generated: (i) that a preceding process is 
responsible for the presence of CFS and the 
outcome of IC/PBS; or (ii) that CFS initiates 
a process that affects the prognosis of 
IC/PBS. Either type of process could be 
physiological, behavioural, structural, 
environmental or another type and could be 
affected by genetics. Many credible 
investigators believe that CFS patients, or 
perhaps a subset of them, exhibit a 
pathophysiology that differs from the other 
syndromes studied here. These include 
infection, immune dysfunction  [ 19 ] and a 
different neuroendocrine profi le. The 
evidence is perhaps strongest for the latter, 
i.e. that hypothalamic – pituitary – adrenal 
(HPA) axis dysfunction might be 
differentially present in individuals with CFS. 
A recent meta-analysis of HPA studies in 
CFS, FM and IBS patients showed that only 
for CFS was there a consistent fi nding of 
HPA hypoactivity  [ 20 ] . Whether this 
precedes or follows the onset of CFS has not 
been determined. 
 The second possibility is that CFS is a 
representative of several syndromes. This 
would be the case if other syndromes were 
associated with CFS and also with a poor 
outcome of IC/PBS, but the latter 
associations were weaker than that with 
CFS. Numerous studies  [ 21 – 26 ] , including of 
these patients  [ 4 ] , have shown these 
syndromes to be associated with CFS; the 
data in  Tables  1 and 2 are consistent with 
but do not prove the existence of the rest of 
this scenario. 
 How might several syndromes be associated 
with each other and with the outcome of 
IC/PBS? One can begin with the two 
hypotheses outlined earlier. The fi rst could 
be expanded to this: (1) that a preceding 
process is responsible for the presence of 
each of the syndromes and the outcome of 
IC/PBS. The second is more complicated: (2a) 
that each syndrome initiates the same 
process that affects the prognosis of IC/PBS; 
or (2b) that each syndrome initiates a 
different process that affects the prognosis 
of IC/PBS. Several pathophysiologies have 
been identifi ed in these syndromes and 
include abnormalities in supraspinal sensory 
processing, in autonomic function, and, 
again, in the HPA axis  [ 27 ] . Whether any of 
these precedes or follows a given syndrome 
has never been determined. 
 These syndromes have many similarities: 
symptom-based diagnoses, prominence of 
pain and fatigue, over-represention among 
women, normal or incidental local histology, 
non-diagnostic laboratory tests, exacerbation 
by stress, co-morbidity, chronicity and 
unknown aetiology  [ 28 ] . Indeed, several of 
the syndromes, FM, CFS and IBS, are 
commonly discussed together as functional 
somatic syndromes (FSSs). Others, CPP and 
migraine, are sometimes included as FSSs; 
and still others, depression and panic 
disorder, are often associated with FSSs  [ 28 ] . 
Whether these similarities suggest a 
commonality in their associations with the 
onset of IC/PBS, i.e. hypothesis 1 or 2a, is 
unknown. 
 We believe that the association of history of 
condom use with IC/PBS outcome is 
spurious, for several reasons: in bivariable 
analysis, the association was not signifi cant; 
in logistic regression analyses, signifi cance 
varied with entry of other variables; there 
was no stepwise increase with frequency of 
use; and there appears to be no literature 
support for a potential mechanism. 
 Because interval therapies might affect the 
endpoint, we integrated them into our 
analyses as possible confounders. Although 
the present study design is inappropriate to 
measure effi cacy of an intervention, the 
fi nding that no interval therapy was directly 
associated with a mild IC/PBS endpoint is 
consistent with the known dearth of 
successful treatments for IC/PBS  [ 1 ] . The 
most likely interpretation for the association 
of interval narcotic use with a poor outcome 
 TABLE  3  Mild IC/PBS endpoint ranked by 
frequency of condom use before the onset of 
IC/PBS 
Condom use
Mild IC/PBS endpoint 
( n / N  [ % ] )
Always 14/36 (39%)




 P  = 0.23. 
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of IC/PBS is that narcotic use was simply a 
marker for more severe IC/PBS symptoms. 
An interesting alternative is that some 
individuals given opioids might actually 
have been made worse because of the 
development of opioid-induced hyperalgesia, 
a phenomenon described in animals that is 
only beginning to be explored in humans 
 [ 29 ] . 
 Of the 61 variables studied, very few were 
revealed as prognostic factors for IC/PBS. 
This replicates studies of other chronic pain 
conditions in which only a handful of 
factors have been shown to predict 
outcome. Those identifi ed are similar to 
ours: symptoms and pain elsewhere, 
depression and anxiety, and baseline severity 
of the pain  [ 18,30 – 34 ] . In these other 
studies, syndrome duration was often 
associated with a poor prognosis. Although 
duration was included in our analyses, it 
was not associated with the endpoint, 
possibly because our participants were 
incident cases with similar, and short, 
durations of IC/PBS. 
 It is intriguing to contemplate that 
identifi cation of the process linking CFS with 
IC/PBS outcome might lead to an 
intervention that would improve the 
prognosis of the latter syndrome. 
 The strengths of the present study are 
exclusion of conditions that could mimic 
IC/PBS, standardized collection of baseline 
and follow-up data, and, in particular, the 
prospective design. Its limitations are that 
only women were studied, patients unable 
to identify an onset date were not enrolled, 
and follow-up was only for the fi rst few 
years of IC/PBS. Additionally, prognosis 
could vary by the recruitment methods of 
IC/PBS patients, e.g. population-based vs 
primary physician practices vs gynaecology 
practices vs urology practices. 
 In conclusion, mild IC/PBS at baseline was 
associated with a mild IC/PBS endpoint. CFS, 
however, predicted a moderate/severe IC/PBS 
endpoint. Whether CFS was uniquely 
associated or represented several co-morbid 
NBSs could not be determined. 
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